您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Paroxetine hydrochloride hemihydrate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Paroxetine hydrochloride hemihydrate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Paroxetine hydrochloride hemihydrate图片
CAS NO:110429-35-1
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品名称
盐酸帕罗西汀半水合物
BRL29060 hydrochloride hemihydrate
BRL29060A hemihydrate
产品介绍
Paroxetine hydrochloride hemihydrate 是一种抗抑郁药,为高效的五羟色胺再摄取抑制剂,能抑制 GRK2 活性,IC50值为 14 μM。
生物活性

Paroxetine hydrochloride hemihydrate is a potent selectiveserotonin-reuptakeinhibitor, commonly prescribed as an antidepressant and has GRK2 inhibitory ability withIC50of 14 μM.

IC50& Target

IC50: 14 μM (GRK2)[3]

体外研究
(In Vitro)

Paroxetine (1 μM and 10 μM) distinctly restrains T cell migration induced by CX3CL1 through inhibiting GRK2. Paroxetine inhibits GRK2 induced activation of ERK[1]. Paroxetine (10 μM) reduces pro-inflammatory cytokines in LPS-stimulated BV2 cells. Paroxetine (0-5 μM) leads to a dose-dependent inhibition on LPS-induced production of TNF-α and IL-1β in BV2 cells. Paroxetine also inhibits lipopolysaccharide (LPS)-induced nitric oxide (NO) production and inducible nitric oxide synthase (iNOS) expression in BV2 cells. Paroxetine (5 μM) blocks LPS-induced JNK activation and attenuates baseline ERK1/2 activity in BV2 cells. Paroxetine relieves microglia-mediated neurotoxicity, and suppresses LPS-stimulated pro-inflammatory cytokines and NO in primary microglial cells[4].

体内研究
(In Vivo)

Paroxetine treatment obviously attenuates the symptoms of CIA rats. Paroxetine treatment clearly prevents the histological damage of joints and alleviates T cells infiltration into synovial tissue. Paroxetine reveals a strong effect on inhibiting CX3CL1 production in synovial tissues[1]. Paroxetine (20 mg/kg/day) reduces the myocyte cross-sectional area in rat and ROS formation in the remote myocardium. Paroxetine reduces the susceptibility to ventricular tachycardia. Paroxetine treatment following MI decreases LV remodeling and susceptibility to arrhythmias, probably by reducing ROS formation[2]. In CCI paroxetine-treated group, paroxetine (10 mg/kg, i.p.) produces hyperalgesia at days 7 and 10 (P<0.01), but a decrease in pain behavior is seen at day 14. Moreover, paroxetine (10 mg/kg) significantly attenuates tactile hypersensitivity when compared to CCI vehicle-treated group[5].

Clinical Trial
分子量

374.83

Formula

C19H20FNO3.Cl H.1/2H2O

CAS 号

110429-35-1

中文名称

盐酸帕罗西汀半水合物;半水盐酸帕罗西汀

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.